Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib
Mené aux Etats-Unis sur 127 patients atteints d'une leucémie lymphoïde chronique réfractaire ou récidivante, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité du vénétoclax, après l'échec d'un traitement par ibrutinib
In recent years, biological and clinical research has identified several targeted agents that are changing the management of patients with chronic lymphocytic leukaemia. In clinical trials,1 the B-cell receptor inhibitor ibrutinib has led to durable responses and longer survival (overall and progression-free) than chemotherapy in patients with this disease. Ibrutinib is now largely used in clinical practice in patients with chromosome 17p deletions or TP53 mutations and relapsed or refractory chronic lymphocytic leukaemia.
The Lancet Oncology 2017